Regulatory considerations for preclinical development of anticancer drugs-Reference-Cited by-同舟云学术

Regulatory considerations for preclinical development of anticancer drugs

Published:1997-12-09 Issue:3 Volume:41 Page:173-185
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:
Short-container-title:Cancer Chemotherapy and Pharmacology

Author:

DeGeorge Joseph J.,Ahn Chang-Ho,Andrews Paul A.,Brower Margaret E.,Giorgio Diana W.,Goheer M. Anwar,Lee-Ham Doo Y.,McGuinn W. David,Schmidt Wendelyn,Sun C. Joseph,Tripathi Satish C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s002800050726.pdf

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Translational PK/PD framework for antibody-drug conjugates to inform drug discovery and development;Xenobiotica;2024-05-13

2. Nonclinical Development of Oncology Drugs;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

3. Preclinical Development of Antibody–Drug Conjugates;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

4. An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose;Cancer Chemotherapy and Pharmacology;2023-07-28

5. Toxicologic Pathology Forum: Opinion on Approaches for Reporting Toxic and Adverse Dose Levels in Nonclinical Toxicology Studies Supporting the Development of Anticancer Pharmaceuticals;Toxicologic Pathology;2023-01